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The potential role of the intestinal microbiota in modulating visceral pain has received increasing 26 
attention during recent years. This has led to the identification of signaling pathways that have 27 
been implicated in communication between gut bacteria and peripheral pain pathways.  In 28 
addition to the well-characterised impact of the microbiota on the immune system, which in turn 29 
affects nociceptor excitability, bacteria can modulate visceral afferent pathways by effects on 30 
enterocytes, enteroendocrine cells and the neurons themselves. Proteases produced by bacteria, 31 
or by host cells in response to bacteria, can increase or decrease the excitability of nociceptive 32 
dorsal root ganglion (DRG) neurons depending on the receptor activated. Short chain fatty acids 33 
generated by colonic bacteria are involved in gut-brain communication, and intracolonic short 34 
chain fatty acids have pro-nociceptive effects in rodents but may be anti-nociceptive in humans. 35 
Gut bacteria modulate the synthesis and release of enteroendocrine cell mediators including 36 
serotonin and glucagon-like peptide-1, which activate extrinsic afferent neurons. Deciphering the 37 
complex interactions between visceral afferent neurons and the gut microbiota may lead to the 38 
development of improved probiotic therapies for visceral pain.   39 
  40 




Visceral pain is a common and debilitating symptom of many digestive diseases, 42 
including inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) (17). Visceral 43 
pain is often resistant to conventional analgesics and can sometimes be exacerbated by opioid 44 
drugs (45, 55).  In light of this, new therapeutics to relieve visceral pain are urgently needed.  45 
Progress towards this goal will be accelerated by a more complete understanding of the 46 
peripheral signaling molecules that modulate nociception in the gut. 47 
The perception of pain is accomplished by neural pathways that connect the gut to the 48 
brain via the spinal cord. The first neurons in this chain have cell bodies in dorsal root ganglia 49 
(DRG), project sensory axons into the gut and form excitatory synapses in the dorsal horn of the 50 
spinal cord. A subpopulation of these neurons, called nociceptors, detects noxious stimuli and 51 
activates pain circuits in the brain. Host-derived mediators from biopsies of IBS and IBD 52 
patients induce hyperexcitability in nociceptive DRG neurons, leading to an exaggerated 53 
response to stimuli such as distension or a bowel movement (16, 26, 60). This change in 54 
nociceptor sensitivity is a major driver of visceral pain.  Superimposed upon these peripheral 55 
changes are changes in central nervous system (CNS) circuits that amplify synaptic inputs from 56 
the periphery (17, 20). Thus, visceral pain results from a combination of peripheral sensitisation 57 
and central plasticity.  Combating these pro-nociceptive influences are host-derived analgesic 58 
substances including endogenous opioids and cannabinoids (22, 124).  This balance between pro-59 
nociceptive and anti-nociceptive influences on DRG neuron excitability dictates the transmission 60 
of pain stimuli to the CNS and the perception of pain. Recent investigations have identified the 61 
gut microbiota as an additional factor in pain modulation, capable of either worsening or 62 
ameliorating pain (8, 88).  Microbial modulation of visceral pain may have translational 63 
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relevance given the changes in microbiota composition associated with IBD and IBS.  Although 64 
intestinal fungi may also play important roles in modulating visceral pain (21), in this review, we 65 
discuss the potential mediators of bacterial modulation of peripheral visceral pain pathways.   66 
A potential role for gut bacteria in visceral pain signalling  67 
The mutualistic relationship that has evolved between bacteria and eukaryotes includes 68 
the ability of commensal bacteria in the gut to influence behavior and pain (24, 40, 88, 96, 122). 69 
Although probiotics have been marketed for the treatment of visceral pain for over a decade, 70 
there is a lack of mechanistic insight into which bacteria, bacterial metabolites, or signaling 71 
pathways are most important. To date, much of the evidence in support of a role for the 72 
microbiota in regulating pain is derived from in vivo studies demonstrating that germ-free mice, 73 
or mice treated with antibiotics that alter the microbiota early in life, have heightened pain 74 
sensitivity (39-41, 74, 88, 90, 98). However, changes to pain sensitivity in germ-free mice may 75 
not be due solely to direct microbial-neuronal interaction, as germ-free mice exhibit a number of 76 
potentially confounding developmental changes to the immune system. Similarly, a study of 77 
visceral pain sensitivity in mice treated with a cocktail of antibiotics reported an increase in 78 
visceral pain accompanied by an increase in colonic myeloperoxidase activity, which is 79 
indicative of immune system activation (126). This suggested a role for inflammatory changes in 80 
nociceptive effects of modulating the microbiota. Although there is potential for bacterial 81 
products to directly activate nociceptive neurons, the evidence until recently, largely supported a 82 
role for epithelial and immune cells in mediating many of the effects of the gut microbiota on 83 
pain pathways in vivo (Table 1) (5, 80, 84, 131). 84 
Bacteria as a source of host modulatory factors 85 
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There is a growing appreciation that the gut microbiota can be considered an endocrine 86 
organ, having the capability to directly or indirectly regulate different gastrointestinal and stress 87 
hormones, which may modify host physiological function (33). Intriguingly, the transfer of 88 
faecal matter from IBS patients is sufficient to evoke visceral hypersensitivity in gnotobiotic rats. 89 
This is not due to changes in mucosal permeability or immune activation, raising the possibility 90 
that bacterial metabolites in IBS patient stool directly modify gut-brain signalling (35). DRG 91 
neurons are capable of “sensing” the presence of microbes. They express functional microbial 92 
pattern recognition molecules, including toll like receptors and nucleotide-binding 93 
oligomerization domains 1 and 2 (91), whose activation can modulate neuronal excitability. 94 
Furthermore, the pathogenic bacterium Staphylococcus aureus directly excites DRG neurons 95 
through a toxin that forms cation-permeable pores in DRG neuronal membranes and through 96 
secretion of N-formylated peptides (32). In contrast to the pro-nociceptive effects of this skin 97 
pathogen however, the commensal gut microbes studied to date have inhibitory effects on DRG 98 
neuron excitability (88, 93, 109).  Given the potential importance of the microbiota as a 99 
modulator of visceral pain, identification of the specific species involved and mediators 100 
responsible will be particularly important. Gut microbes produce a plethora of neuro-active 101 
compounds such as proteases (116), short chain fatty acids (SCFA) (99) and also classical 102 
neurotransmitters such as γ-amino butyric acid (GABA), dopamine and norepinephrine (94).  We 103 
will consider the available evidence in support of a role for specific bacterial mediators in terms 104 
of their capability to directly access and act upon nerve circuits to modulate their function (39, 105 
88, 137). We will also discuss microbe-mediated modulation of visceral pain pathways by using 106 
immune cells and enterocytes as cellular transducers (Figure 1).   107 
Direct signalling by bacterial metabolites 108 




Extracellular proteases, in particular serine and cysteine proteases, are important modulators of 110 
visceral pain (127). Proteases are released from many eukaryotic cell types, including mast cells, 111 
neutrophils and enterocytes (97, 104). Recent in vivo and in vitro work has identified the gut 112 
microbiota as an important source of proteases (116) capable of affecting peripheral pain 113 
pathways (8, 81, 109).  Pain regulation by proteases most often occurs through the activation of 114 
protease activated receptors (PARs). PARs are a family of four G-protein coupled receptors that 115 
lack conventional ligand binding sites and are instead activated via protease-mediated hydrolysis 116 
of amino acid residues.  Upon protease cleavage, a tethered ligand within the receptor is revealed 117 
that activates intracellular signaling pathways (97). The net effect of receptor signaling depends 118 
not just on the PAR subtype involved but the specific amino acids hydrolysed (97). A consistent 119 
finding from numerous laboratories is that PAR-2 activation causes sustained hyperexcitability 120 
of DRG neurons (6, 34, 51, 136).  Indeed, activation of nociceptor PAR-2 by mast cell tryptase 121 
and enterocyte derived trypsin-3 (85, 104) has been implicated in visceral pain (12, 63). 122 
However, nociceptive neurons also express PAR-1 and PAR-4. Activation of PAR-1 and PAR-4 123 
reduces DRG neuron excitability and is anti-nociceptive (10, 11, 66, 104). PAR-2 activation in 124 
vivo by cysteine proteases in fecal supernatants from IBS patients enhanced the visceromotor 125 
response to colorectal distension in rats, an in vivo assay of visceral pain.  In contrast, activation 126 
of PAR-4 by commensal microbes has an analgesic effect in vivo and in vitro (81, 109).  The 127 
opposing effects of PAR-2, PAR-1 and -4 suggest that the balance between PAR-2, and PAR-1 -128 
4 activation could be a critical determinant of nociception.   129 
While it seems clear that activation of PARs by proteases derived from the microbiota 130 
can modulate pain, an important unresolved issue is whether these proteases exert this influence 131 
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via actions on mucosal cells, immune cells or directly on DRG nerve terminals.  The intestinal 132 
barrier is comprised of a mucus-coated epithelial monolayer whose integrity is maintained by 133 
tight junction proteins, which regulate the paracellular movement of luminal molecules. Beneath 134 
the epithelial layer, intrinsic and extrinsic neurons relay neural information both within the GI 135 
tract but also between the gut and the CNS. However, evidence that this communication system 136 
extends beyond the epithelial barrier to the microbially-dominated environment of the gut lumen, 137 
has resulted in it being referred to as the microbiota-gut-brain axis (19, 47, 76). It appears that at 138 
least in some circumstances, the impact of PAR activation on visceral pain is due to modulation 139 
of epithelial barrier function. Using a model of IBS in rodents, Miquel and colleagues found that 140 
proteases derived from Faecalibacterium prausnitzii inhibited the increase in visceral pain that 141 
results from neonatal maternal separation.  In this case, the decrease in visceral pain was ascribed 142 
to PAR-4 mediated reversal of the increase in mucosal permeability in this model of visceral 143 
pain (81).  Faecal supernatants from patients with chronic ulcerative colitis led to a decrease in 144 
visceromotor response to colorectal distention due to activation of PAR-4 (8). In a separate 145 
study, serine proteases from Faecalibacterium prausnitzii acted directly on nerve terminals to 146 
inhibit colonic sensory nerve spike discharge and reduced the excitability of colon-projecting 147 
DRG neurons via PAR-4 activation (109). Furthermore, these proteases reversed DRG neuronal 148 
hyperexcitability caused by the dextran sulphate sodium model of colitis in mice (109).    149 
Opposite findings have been reported for microbial activation of PAR-2. Luminal 150 
administration of faecal supernatants from patients with diarrhea-predominant IBS increased 151 
visceral pain sensitivity and impaired mucosal barrier function in vivo via PAR-2 activation (49).   152 
Consistent with the ability of luminal proteases to have pronociceptive effects, luminal 153 
administration of the PAR-2 activating serine protease, cathepsin S, was sufficient to increase 154 
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visceromotor responses in mice in a PAR-2-dependent manner (27).  Similarly, activation of 155 
PAR-2 by host derived proteases causes a sustained increase in the excitability of mouse DRG 156 
neurons (67). Thus, although there is abundant evidence that activation of neuronal PAR-2 has 157 
pro-nociceptive effects, it remains unclear whether neuronal PAR-2, in addition to mucosal 158 
PAR-2, participates in the pro-nociceptive effects of bacterial proteases.  Cell-specific receptor 159 
knockout strategies will be important tools in identifying which PAR-expressing cells are most 160 
important to visceral pain modulation in vivo.   161 
In addition to microbial-derived proteases, the microbiota is a rich source of protease 162 
inhibitors (54) including siropins, which has been shown to mitigate the effect of host-derived 163 
proteases implicated in IBD pathogenesis (82).  A recent study using a rodent model of post-164 
inflammatory hypersensitivity provided valuable evidence that synthetic protease inhibitors can 165 
mitigate the pro-nociceptive effects of proteases in this model (28).  It therefore appears that the 166 
balance between the activity of proteases and protease inhibitors can influence visceral 167 
perception and may be an important target for novel therapeutics (128).   168 
Short chain fatty acids 169 
Short chain fatty acids (SCFAs) are produced by the fermentation of dietary polysaccharides that 170 
are metabolized by the anaerobic bacteria found in the cecum and colon. Formate, acetate, 171 
butyrate, and propionate are the major byproducts of this fermentation process (83).  Earlier 172 
reports have identified Fecalibacterium prausnitzii, Eubacterium rectale, Eubacterium hallii and 173 
Roseburia faecis as bacteria capable of producing butyrate. Likewise, acetate and pyruvate are 174 
produced by enteric bacteria such as Blautia hydrogenotrophica; propionate, on the other hand, 175 
can be produced by Bacteroidetes and Firmicutes (72). 176 
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 A well-established effect of butyrate is inhibition of bowel inflammation and 177 
enhancement of mucosal repair, which would have an indirect effect on inflammatory visceral 178 
pain (103). SCFAs also modulate the enteric nervous system (113) and have been posited as an 179 
important mediator of microbiota-gut-brain communication (88). Microbial dysbiosis, due to the 180 
administration of antibiotics or due to modulation of diet, led to a decrease in SCFA and an 181 
increase in visceral sensitivity (38, 90, 100, 112).  This suggests an association between SCFA 182 
and visceral pain modulation but does not directly establish a causal relationship. Contrary to 183 
these studies, when SCFAs were administered to control rats and rats with TNBS-induced colitis, 184 
visceral hypersensitivity was not improved by any of the SCFAs (acetate, propionate and 185 
butyrate) used (121). In fact, butyrate administration decreased the noxious pressure threshold in 186 
rats, indicating a pronociceptive effect; this phenomenon was more pronounced in control rats 187 
than in TNBS- treated rats. This observation is supported by a report that rectal administration of 188 
sodium butyrate induced colonic hypersensitivity in rats (133). This pronociceptive effect was 189 
associated with neuronal activation of extracellular signal related kinase (ERK)1/2 and an 190 
enhancement of DRG neuronal excitability. However, a study of healthy human volunteers 191 
concluded that butyrate treatment induced a dose-dependent reduction of visceral sensitivity 192 
(125). In summary, despite evidence implicating SCFAs in mediating gut-brain communication 193 
in general, there are conflicting findings regarding the role of SCFAs in modulating visceral 194 
pain.    195 
Microbial neurotransmitters and neurotrophic factors 196 
Microbial depletion and recolonization studies have linked microbial modification of neuroactive 197 
compounds in the gut-brain communication axis to diseases of the peripheral and central nervous 198 
system (119). Germ-free studies illustrate the crucial role of microbes in the development of 199 
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brain function and expression of central neurochemicals (15, 23) however, antibiotic treatment in 200 
mature animals can avoid the confounding developmental effects of early-life microbial 201 
alterations. Hoban and colleagues reported modification of central monoamines, serotonin and 202 
brain derived neurotrophic factor (BDNF) following sustained antibiotic administration to adult 203 
rats. These changes were accompanied by altered behaviors and diminished visceral pain 204 
sensitivity to colorectal distension (58). Interestingly, antibiotic-related alterations in 205 
neurotransmitters can be long-lasting and have different functional outcomes when administered 206 
early in life. A gender-specific increase in visceral sensitivity, which was linked to decreases in 207 
spinal cord expression of transient receptor potential (TRP)V1, α2A adrenergic receptors and 208 
cholecystokinin B receptors, was noted in male rats treated with vancomycin from postnatal days 209 
4-13 (90).  210 
In addition to modification of host neurotransmitters, microbes also exhibit the capacity 211 
to secrete functional neurotransmitters and neurotrophins. GABA, the major inhibitory 212 
neurotransmitter, is synthesized by several Lactobacilli and Bifidobacteria (14, 129). As GABA 213 
receptor agonists can suppress visceral pain responses to colorectal distension (56)  and 214 
inflammation-induced pain signals (73), this may contribute to nociceptive signaling from the 215 
gut (62). Dopamine and norepinephrine, which have reported anti-nociceptive effects of visceral 216 
pain sensitivity (37, 92), are also produced by several gut bacterial species, including Bacilli and 217 
Escherichia (94, 129). BDNF, an important neurotrophic regulator of synaptic plasticity and 218 
neurogenesis, is purported to be a hallmark of altered microbiota-gut-brain axis signaling, given 219 
that its expression is altered in germ-free mice (87, 120) and in antibiotic- (58) and prebiotic-220 
treated mice (107). Moreover, BDNF is expressed on TRPV1‐expressing nociceptive DRG 221 
neurons (132) and neutralizing BDNF blocked visceral hypersensitivity in inflammatory colonic 222 
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hypersensitivity (42). In IBS patients, increased expression of nerve growth factor (NGF) 223 
correlated with visceral pain sensitivity (134), which may be due to sensitization of pro-224 
nociceptive receptors on primary afferent neurons. Indeed, NGF increases TRPV1 expression in 225 
DRGs (110).  In the context of microbial modification of host molecules, an in vitro study 226 
demonstrated that  Lactobacillus rhamnosus induces anti-inflammatory effects in human 227 
epithelial cells which is mediated by NGF (75). Although intriguing, evidence that gut bacteria 228 
have the capacity to secrete neurotransmitters and neurotrophins, does not explain how 229 
neuromodulatory molecules in the external environment of the gut lumen can modify gut-to-230 
brain nociceptive signalling. As afferent nerves do not reach through the epithelium into the gut 231 
lumen, further mechanistic studies are needed to determine how bacterially-derived 232 
neuromodulatory factors can cross the gut barrier to influence gut-brain signalling. 233 
 234 
Indirect signaling  235 
Serotonin secretion from Enterochromaffin cells 236 
Serotonin has long been recognised as a critical regulator of gut function, inflammation and pain 237 
(50, 77). Accordingly, the release of serotonin from enterochromaffin (EC) cells and its sites of 238 
action are important therapeutic targets for visceral pain. Two recent independent reports 239 
delineated the ability of microbes to modulate serotonin synthesis by EC cells. One study 240 
reported an increase in serotonin production in mice colonised with human fecal microbiota, 241 
compared to germ-free mice (99).  This was associated with an increase in expression of 242 
tryptophan hydroxylase 1 (TPH1), the rate limiting enzyme for serotonin synthesis in EC cells. 243 
Consistent with the ability of microbial metabolites to increase TPH1 expression, the SCFAs, 244 
sodium acetate and sodium butyrate, increased TPH1 expression in a human-derived EC cell 245 
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line. The second study identified spore-forming bacteria as important modulators of serotonin 246 
production by EC cells, and revealed that this effect occurred in the colon but not the small 247 
intestine (135).  Furthermore, EC cell serotonin modulation by microbiota was also observed in 248 
RAG1 knockout mice which lack T and B cells, suggesting a direct action on EC cells rather 249 
than an indirect effect via immunomodulation.  SCFAs were also implicated as modulators of EC 250 
cell function, which may be an important mechanism of pain modulation by microbiota. Other 251 
bacterial metabolites, such as bile acids and p-aminobenzoate, have also been implicated in 252 
regulating serotonin production. From these findings it appears that several bacterial signaling 253 
pathways depend on the release of serotonin from EC cell as a means of modulating gut function, 254 
inflammation and visceral pain.  In addition to microbial modulation of serotonin release, Kwon 255 
and colleagues have recently (69) demonstrated that host-derived serotonin has direct and 256 
species-specific effects on the growth of commensal microbes in vivo and in vitro.  Furthermore, 257 
the secretion of the anti-microbial peptide α-defensin from the HT-29 epithelial cell line was 258 
inhibited by serotonin (69).  These findings illustrate the complex and bidirectional nature of the 259 
interactions between gut microbes and enterochromaffin cells. 260 
GLP-1 secretion from L-cells 261 
Similar to EC cells, GLP-1-secreting L-cells may act as chemosensory sentinels, conveying 262 
information about the luminal environment to the host. L-cells are polarised, electrically 263 
excitable enteroendocrine cells (31), which sense the arrival of nutrients, such as glucose and 264 
amino acids, in the small intestine. Despite the reduced probability of nutrients being present, the 265 
abundance of GLP-1-secreting L-cells increases towards the distal end of the GI tract (117). 266 
Consistent with the contents of the colonic lumen, L-cells in this region express receptors for 267 
SCFAs and bile acids (101, 123). Moreover, dietary supplementation with SCFAs (123), the 268 
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introduction of specific commensal strains (9, 118) or antibiotic treatment (61) increased GLP-1 269 
levels. Somewhat counter-intuitively, one study determined that serum GLP-1 was also elevated 270 
in germ-free mice (108), although other researchers found that germ-free mice exhibited a strong 271 
state of GLP-1 resistance, with impaired GLP-1 evoked gut-brain signalling and enteric nervous 272 
system function (52). A clinical trial in IBS patients found that administration of a GLP-1 273 
mimetic reduced acute abdominal pain in patients (57). GLP-1 can act as a classical endocrine 274 
hormone, however GLP-1 also has direct neurostimulatory actions on vagal afferent neurons 275 
(78). Furthermore, there is evidence of direct, physical contact between a pseudopod-like 276 
elongation of L-cells and afferent nerve fibres (18), providing for a potential neural signalling 277 
pathway in the modification of GI function. Thus, L-cells are appropriately positioned to 278 
facilitate cross-barrier signalling from the gut lumen to the host peripheral nervous system and 279 
on to the CNS, and should be investigated as a potential modulator of visceral pain.  280 
Histamine release from mast cells 281 
Histamine, which is mainly secreted by mast cells, promotes allergic inflammation but also 282 
appears to play a role in visceral nociception. Indeed, histamine-containing secretions from IBS 283 
patient mucosal mast cells have been shown to excite rat nociceptive visceral afferent nerves, 284 
and are thus likely to participate in relaying visceral pain signals (13). Of the four histamine 285 
receptor subtypes, H1R and H2R are most prevalent in the gut. Similar to the opposing actions of 286 
PAR subtypes described earlier, activation of H1R promotes pro-inflammatory pathways (30), 287 
whereas H2R suppresses inflammation (111). In patients with IBD, reduced expression of H2R 288 
may underlie decreased suppression of TLR-induced cytokine secretion in this patient population 289 
(111). H1R antagonists decreased abdominal pain in IBS patients (68) and in a rat model of 290 
visceral hypersensitivity (115). Moreover, IBS patient biopsies display increased expression of 291 
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H1R (106). Histamine may also be secreted by bacterial species such as Lactobacillus reuteri 292 
6475, a commonly-used probiotic (114), which can reduce intestinal inflammation (48) and may 293 
also have an impact of visceral pain sensitivity. 294 
Vagal afferent pathways 295 
Vagal afferent neurons may also participate in the sensory arm of gut-brain nociceptive 296 
signaling. Although electrical stimulation of abdominal vagal afferents does not induce pain per 297 
se, nociceptive signaling may be modulated by vagal activity (7). Vagal nerve activation may in 298 
fact, induce an inhibitory modulation of chemically or mechanically-provoked insults (29, 53), as 299 
noted in a rat model of visceral pain where vagal nerve stimulation had an anti-nociceptive effect 300 
(138). Vagal afferent terminals are located within enteric ganglia, and in the smooth muscle and 301 
mucosal layers, where they are well-positioned to sense chemo-nociceptive signals (70, 95, 130).  302 
Given the essential role of the vagus nerve in mediating microbe-gut-brain communication (15, 303 
23), future work should address whether modulation of vagal afferent pathways by bacteria 304 
impacts visceral pain. 305 
Conclusions 306 
There is abundant evidence that the microbiota is capable of modifying visceral pain in vivo.  307 
However, clinical trials of probiotics as therapies for visceral pain have yielded equivocal results.  308 
This may reflect patient heterogeneity, patient compliance, or the variety of probiotic 309 
formulations used, which is in turn reflects a relative paucity of mechanistic work identifying the 310 
most important microbial species and mediators to target for clinical benefit.  A number of issues 311 
remain unresolved in bridging the gaps between our present state of knowledge and successful 312 
manipulation of the gut microbiota to alleviate pain.  For example, the detection of high 313 
threshold noxious stimuli in rodents is accomplished by visceral afferent neurons with terminals 314 
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that lie along serosal and mesenteric blood vessels (25).  Furthermore, based on a limited number 315 
of recordings from visceral afferent neurons from human bowel, the majority of afferent 316 
terminals that have been characterized to date have been located in the muscle and vasculature.  317 
Thus, it appears that luminal mediators from the microbiota may have traverse the epithelial 318 
barrier and enter the circulation to access and modulate gut nociceptive terminals.  Future studies 319 
of full-thickness resected bowel preparations from patients may provide insight into how the 320 
luminal microbiota accesses these terminals. Another potential caveat when translating findings 321 
from rodents to patients is that signaling mechanisms that are inhibitory in rodents may be 322 
excitatory in patients, and vice versa. A recent Ca2+ imaging study of PAR activation in human 323 
DRG neurons reported that PAR-1 activation in human neurons is excitatory (43), whereas PAR-324 
1 is inhibitory in rodents (10).    By increasing mechanistic insights into the interplay between 325 
the microbiota and peripheral pain pathways, particularly using patient microbiota and human 326 
DRG neurons (59), improved therapies that harness the analgesic properties of the microbiota 327 
may soon be on the horizon.   328 
 329 
  330 
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Table 1: In vivo studies of the effects of probiotics on visceral pain. 791 
Probiotic strain Reference Main finding Proposed mechanism 





Neonatal zymosan-treated rats treated 
with probiotic did not exhibit visceral 




Lactobacillus reuteri (93) Inhibited the bradycardia induced by painful gastric distension in rats  TRPV1 modulation 
Lactobacillus paracasei 
(126) Normalized visceral sensitivity to CRD in antibiotic treated mice in mice Immunomodulation 
(46) 
Prevented the maternal deprivation 
increased visceral sensitivity in response 
to CRD in rats 
Epithelial barrier regulation 
Lactobacillus acidophilus 
(105) Normalized visceral pain responses to CRD in mice and rats 
Altered epithelial 
expression of opioid and 
cannabinoid receptors 
(102) 
Reduced bloating symptoms in patients 
with functional bowel diseases 
experiencing abdominal pain in females 
Modulated μ-opioid 
receptor expression and 
activity  
Lactobacillus farciminis 
(3) Reversed visceral hypersensitivity induced by partial restraint stress (PRS) in rats Epithelial barrier regulation 
(2) 
Inhibited Fos protein expression at spinal 
and supraspinal levels as a marker of 
visceral pain in response to  CRD in rats 
after PRS 
None specified 
Bifidobacterium infantis  (64) Reversed post-inflammatory (TNBS) visceral hypersensitivity in rats Immunomodulation 
Bifidobacterium lactis (1) Inhibited PRS-induced visceral hypersensitivity in rats Epithelial barrier regulation 
Bifidobacterium  longum 
and Lactobacillus 
helveticus  
(4) Reduced chronic stress-induced visceral hypersensitivity in mice 
Regulation of 
hypothalamic-pituitary-
adrenal axis  







(79) Reduced CRD-induced visceral pain behaviours in rats  None specified 
Bifidobacterium infantis  
or Lactobacillus salivarius  (89) 
Bifidobacterium infantis decreased 
visceral pain more than Lactobacillus 








Reversed visceral hypersensitivity induced 
by water-avoidance stress or IBS fecal 
supernatant administration in mice  
Epithelial barrier regulation 
VSL#3 Bifidobacterium 
(B. longum, B. infantis 
and B. breve); 
Lactobacillus (L. 
acidophilus, L. casei, L. 
delbrueckii ssp. 





Early life administration of VSL#3 reduced 
visceral pain perception in a model of IBS 
in rats 
Altered colonic expression 
of genes influencing pain 
and inflammation 
(36) Decreases acetic-acid-induced visceral hypersensitivity in rats Epithelial barrier regulation 
(71) Decreases acetic-acid-induced visceral hypersensitivity in rats  Immunomodulation 
Faecalibacterium 
prausnitzii  (81) 
Decreased colonic hypersensitivity 
induced by either NMS in mice or partial 
restraint stress in rats 
Epithelial barrier regulation 
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Figure 1: Microbial modulation of visceral afferent pathways 793 
The figure illustrates potential mechanisms by which microbes in the gut lumen could modify 794 
afferent signaling from the gut to the central nervous system. The microbiota can affect the 795 
sensitivity of peripheral pain pathways by direct effects on the peripheral terminals of DRG 796 
neurons or indirectly by changing mediator release from enteroendocrine cells, immune cells or 797 
enterocytes.  NTS: nucleus tractus solitarius, DRG: dorsal root ganglion, ENS: enteric nervous 798 
system, ECC: enterochromaffin cell, TLRs: Toll-like receptors. 799 
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